Sponsor Check › Person
Named as an officer, director or promoter on SEC Form D filings · MA, CA, MN, TX · May 28, 2009 → Jun 1, 2023
Data last updated Oct 23, 2026, 5:45 PM ET · Courts (RECAP) last checked: Oct 24, 2026, 2:18 AM ET · SEC enforcement last checked: covered by the index scan as of Oct 24, 2026, 2:50 AM ET
Ansbert Gadicke is listed as an executive officer, director, and promoter on 40 SEC Form D filings by 21 issuers between May 2009 and Jun 2023. Largest by amount reported sold: MPM BioVentures 2022, L.P. (Boston, MA — pooled investment fund — 2022–2023; $351M reported sold to 45 investors), MPM BioVentures 2014, L.P. (Cambridge, MA — pooled investment fund — 2014–2015; $347.3M reported sold to 94 investors), Oncology Impact Fund 2, L.P. (Cambridge, MA — pooled investment fund — 2021; $326.8M reported sold to 31 investors), MPM BIOVENTURES V, L.P. (Boston, MA — pooled investment fund — 2010; $140M reported sold to 24 investors), Radius Health, Inc. (Cambridge, MA — pharmaceuticals — 2011; $126.9M reported sold to 36 investors) and 16 more (all listed below).
What this means That is a lot of deals — 21 separate companies raised money with this person listed as executive officer, director, and promoter, over about 14 years. Across those companies the filings report $2.08B sold in total.
Listed alongside Luke Evnin (13 shared filings), Todd Foley (11 shared filings), Vaughn Kailian (8 shared filings), MPM Asset Management LLC (6 shared filings, management entity), Denise Pollard-Knight (5 shared filings) and 96 others.
What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Ansbert. Each name links to their own page.
The issuers belong to 3 sponsor groups: Mpm Bioventures (2 issuers, $0 reported sold, 2018), Mpm (2 issuers, $369.8M reported sold, 2014–2015) and Cerimon (3 issuers, $137.2M reported sold, 2009–2025).
What this means This person is listed across more than one sponsor team; each group page shows that team's full track record.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AR, AZ, CA, CT, DE, FINRA, GA, HI, ID, LA, ME, MO, MS, MT, NASAA, NC, NH, NM, OR, RI, TX, WA) — none found.
What this means Nothing turned up where we looked (3 sources). That does not prove there is nothing — it means none was found in those sources on that date.
We compared 40 public filings for Ansbert Gadicke and found 20 differences, 7 worth asking the sponsor about: Amount sold went down between filings; Investor count went down between filings; and more below.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.
Community search for Ansbert Gadicke has not run yet — it is joining a line of 20,438 names; searches run around the clock at the hosts' allowed rate. Searched so far: 305 names.
Community comments are quoted as written by their authors. Sources searched: BiggerPockets forums (via DuckDuckGo, Brave, Bing and BiggerPockets search) and Reddit (search feed + public archive).
Five things investors ask first. Items still in human review are counted, not shown.
None found in sources searched — federal courts (CourtListener / RECAP), checked Oct 24, 2026
Sources searched: CourtListener bulk data (RECAP dockets as of 2026-09-30; recall-first rule 10-24) — federal district + bankruptcy courts State courts: not covered (one-tap state court links under Look further). PACER: not searched. · Last checked Oct 24, 2026, 2:18 AM ET.
State courts: not covered (one-tap state court links under Look further). No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.
None found in sources searched — SEC enforcement releases (index scan as of Oct 24, 2026, 2:50 AM ET) · state securities regulators: NV (crawled Oct 23, 2026)
SEC enforcement searched: SEC litigation releases and administrative proceedings — respondent names in the sec.gov index titles (30,205 releases, 1995-09-19 to 2026-10-23); release text is read only to confirm a candidate. Names that appear only in the body of a release are not found. — Searched SEC litigation releases and administrative proceedings (1995→ / 2007→) (30,205 records as of Oct 24, 2026, 2:50 AM ET) — nothing matched Ansbert Gadicke..
State securities regulators: Securities regulators searched (3,318 actions): AZ Corporation Commission Securities Division (411 actions, 2017–2026), CA DFPI (25 actions, 2007–2024; listing starts 2002), DE DOJ Investor Protection Unit (257 actions, 1987–2026), TX State Securities Board (586 actions, 2006–2026), WA DFI (2,039 actions, 2001–2026) — 16 of 12,159 DFPI respondent pages read so far; sponsor-name matches are read first — last crawled Oct 23, 2026, 9:57 PM ET. No machine-readable public listing today for IA, IN, KS, MI, NE, NV (see docs/state-regulators.md).
None found in sources searched — federal bankruptcy courts (CourtListener / RECAP), checked Oct 24, 2026
Sources searched: Federal bankruptcy courts via CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not covered (one-tap state court links under Look further). PACER: not searched (RECAP only). · Last checked Oct 24, 2026, 2:18 AM ET.
State courts: not covered (one-tap state court links under Look further). No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.
Comparisons cover issuers and sponsor groups — see the issuer pages under Deals
20 differences found between the filings for Ansbert Gadicke — 7 worth asking about (compared 40 filings on Oct 24, 2026)
United States Bankruptcy Court, S.D. Florida. docket "ALL FLORIDA DELIVERY SERV. INC v. Cordo" filed May 10, 2013, closed Nov 27, 2013. David Cordo (listed on the same filings) is listed as Defendant ("Cordo"). Our match estimate: 70%.
What this means A bankruptcy filing was found. Many are old or personal and have nothing to do with the deal — but ask what it was and when it closed.
United States Bankruptcy Court, E.D. Pennsylvania docket "Seguine v. Ford Motor Credit Company" filed Feb 14, 2002, closed Jun 10, 2002. Edward S. Seguine, Jr. (listed on the same filings) is listed as Plaintiff ("Seguine"). Our match estimate: 70%.
What this means A bankruptcy filing was found. Many are old or personal and have nothing to do with the deal — but ask what it was and when it closed.
United States Bankruptcy Court, E.D. Pennsylvania docket "Seguine v. Citifinancial Mortgage" filed Feb 14, 2002, closed Apr 30, 2002. Edward S. Seguine, Jr. (listed on the same filings) is listed as Plaintiff ("Seguine"). Our match estimate: 70%.
What this means A bankruptcy filing was found. Many are old or personal and have nothing to do with the deal — but ask what it was and when it closed.
The Jun 24, 2010 filing says $1,000,000 sold; the Nov 15, 2010 Form D/A says $232,957 sold — $767,043 less.
What this means Amounts sold normally only go up as a raise continues. A drop can mean investors were refunded, a figure was corrected, or an earlier number was wrong. Ask the sponsor which it was.
The Sep 9, 2009 filing says $1,500,003 sold; the Apr 2, 2010 Form D says $750,000 sold — $750,003 less.
What this means Amounts sold normally only go up as a raise continues. A drop can mean investors were refunded, a figure was corrected, or an earlier number was wrong. Ask the sponsor which it was.
The Feb 12, 2010 filing says $140,048,150 sold; the Feb 12, 2010 Form D says $69,140,000 sold — $70,908,150 less.
What this means Amounts sold normally only go up as a raise continues. A drop can mean investors were refunded, a figure was corrected, or an earlier number was wrong. Ask the sponsor which it was.
The Jun 24, 2010 filing reports 10 investors; the Nov 15, 2010 Form D/A reports 9 investors.
What this means Investor counts normally only grow. A smaller number can mean investors left or were refunded, or a count was corrected. Ask the sponsor what happened.
The Feb 12, 2010 filing reports 24 investors; the Feb 12, 2010 Form D reports 9 investors.
What this means Investor counts normally only grow. A smaller number can mean investors left or were refunded, or a count was corrected. Ask the sponsor what happened.
The Oct 2, 2018 Form D reports $30,000,000 sold and $6,837,146 of the proceeds used for payments to officers, directors or promoters. Issuer's note: "Pursuant to Redeemable Preferred Stock Redemption Agreement".
What this means The filing reports how much of the money raised was paid to insiders. Over 10% is high for most deals. Ask what it paid for.
Orna Therapeutics Holdings, LLC (last filing Aug 23, 2022; $120,599,993 sold of $300,000,000); MPM ONCOLOGY INNOVATIONS FUND LP (last filing Feb 26, 2020; $98,879,004 sold of $200,000,000); MPM BIOVENTURES 2018 (B), L.P. (last filing Feb 23, 2018; $0 sold of $400,000,000); MPM BIOVENTURES 2018, L.P. (last filing Feb 22, 2018; $0 sold of $400,000,000); Mitokyne, Inc. (last filing Oct 17, 2013; $5,222,321 sold of $45,000,000); Elixir Pharmaceuticals, Inc. (last filing May 28, 2009; $11,994,995 sold of $25,000,000). Each has no filing in more than two years and reported under half its target sold.
What this means An issuer whose last filing is more than two years old and reported under half its target sold. The raise may have closed early or quietly stopped. Ask what happened to each.
Form D filed 475 days after the first sale — Oncology Impact Fund 2, L.P. · Form D filed 161 days after the first sale — Sideris Pharmaceuticals, Inc. · Form D filed 176 days after the first sale — MPM BIOVENTURES V, L.P. · Form D filed 16 days after the first sale — iTeos Therapeutics, Inc.
What this means Late notices are common and carry no penalty by themselves. A pattern of late paperwork is worth asking the sponsor about.
No amendment in the last 12 months on an offering that may still be open — MPM BioVentures 2022, L.P. (latest filing Jun 1, 2023) · No amendment in the last 12 months on an offering that may still be open — Orna Therapeutics Holdings, LLC (latest filing Aug 23, 2022) · No amendment in the last 12 months on an offering that may still be open — Oncology Impact Fund 2, L.P. (latest filing Nov 22, 2021) · No amendment in the last 12 months on an offering that may still be open — Allovir, Inc. (latest filing Oct 2, 2018) · No amendment in the last 12 months on an offering that may still be open — CHIASMA, INC (latest filing Mar 5, 2015) · and 5 more
What this means SEC rules expect a yearly amendment while an offering is still going. Ask the sponsor which of these raises have closed.
Offering amount lowered between filings — MPM ONCOLOGY INNOVATIONS FUND LP · Offering amount changed between filings — MPM BioVentures 2014, L.P. · Offering amount lowered between filings — MPM BioVentures 2014, L.P. · Offering amount changed between filings — MPM Bio 2014 NVS Strategic Fund, L.P. · Offering amount changed between filings — CHIASMA, INC · and 4 more
What this means Targets change as deals grow or shrink. Ask whether later money has the same terms.
listed as "Ansbert Gadicke" on 34 filings (from May 28, 2009), and "Ansbert K. Gadicke" on 6 filings (from May 31, 2011).
What this means Same person, written differently — a middle name or suffix left off, or spelled another way. It is normal, but check that the full legal name matches your subscription documents.
"$1,000,001 - $5,000,000" (Apr 2, 2015); then "$5,000,001 - $25,000,000" (Apr 7, 2015).
What this means This is the size band the issuer picks for itself on the form. A change can mean the business grew or shrank — or that it chose not to say. Ask for current numbers.
This page covers filings where the address state is MA or CA or MN or TX. A separate record, "Ansbert Gadicke" with address state PA or NJ, is listed on 4 filings — most recently by Reunion Neuroscience, Inc. (Sep 9, 2025). The two records do not overlap in time: this page runs May 28, 2009 to Jun 1, 2023; the other runs May 6, 2024 to Sep 9, 2025.
What this means Could be the same person who moved, or two people with the same name. We keep them apart until a filing ties them together. Check both pages before you decide.
The people listed on the May 5, 2022 filing give Cambridge, MA; on the Jun 1, 2023 filing they give Boston, MA. The address now on file (399 Boylston Street, Suite 1100, Boston, MA) is a registered-agent or shared-office address used by 16 issuers.
What this means A registered agent's address is a mailbox, not where the team works. Ask where the business actually operates.
The people listed on the Oct 2, 2018 filing give New Brighton, MN; on the May 22, 2019 filing they give Houston, TX. The address now on file (2925 Richmond Ave., Suite 1274, Houston, TX) is a registered-agent or shared-office address used by 16 issuers.
What this means A registered agent's address is a mailbox, not where the team works. Ask where the business actually operates.
The people listed on the May 29, 2014 filing give Boston, MA; on the May 22, 2015 filing they give Cambridge, MA.
What this means Businesses move; this just shows the two places and dates. If you were told one city and the forms say another, ask which is current.
MA on 33 filings (May 28, 2009 to Jun 1, 2023); CA on 5 filings (Sep 9, 2009 to Nov 15, 2010); MN on 1 filing (Oct 2, 2018); TX on 1 filing (May 22, 2019).
What this means The address on a Form D is usually the company's, not the person's home, so this often just reflects different companies. It can also mean a move. Nothing wrong by itself.
What is compared: every Form D and D/A we hold for this subject, side by side — filing dates vs. first-sale dates (the 15-day rule), amendment timing on open offerings (the yearly-amendment expectation), amounts sold, investor counts, offering amounts and minimums across amendments, industry and size bands, addresses, how each person's name and role is written, paid sellers' CRD numbers, and (for groups) where the member companies were formed and sit. Everything is as filed by the issuer; the SEC does not check it. Differences are common and usually have ordinary explanations — we show both values, the dates, and the source so you can ask. As of Oct 24, 2026.
4 of 26 offerings report sales commissions totalling $13,543,968; 0 report finder's fees; 2 report proceeds to related persons totalling $8,537,146. (includes amounts the issuer reported as estimates)
| Offering (latest filing) | Sales commissions | Finder's fees | To insiders | Paid to sell it | Source |
|---|---|---|---|---|---|
| Jun 1, 2023 D/A MPM BioVentures 2022, L.P. File 021-444554 | $1,050,000 | $0 | $0 | J.P. MORGAN SECURITIES LLC BrokerCheck CRD 79 ↗ | EDGAR ↗ |
| Dec 27, 2022 D NextPoint Therapeutics, Inc. File 021-468792 | $0 | $0 | $1,700,000 (est.) | None listed on this filing | EDGAR ↗ |
| Aug 23, 2022 D Orna Therapeutics Holdings, LLC File 021-456682 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Nov 22, 2021 D Oncology Impact Fund 2, L.P. File 021-422030 | $11,919,100 | $0 | $0 | UBS FINANCIAL SERVICES INC. BrokerCheck CRD 8174 ↗ | EDGAR ↗ |
| Apr 9, 2020 D iTeos Therapeutics, Inc. File 021-364700 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Feb 26, 2020 D/A MPM ONCOLOGY INNOVATIONS FUND LP File 021-315855 | $0 (est.) | $0 | $0 (est.) Certain persons named in Item 3 or affiliate(s) thereof may receive payments deemed to be made from the proceeds of the offering, including management fees. The amount of such payments cannot be estimated at this time. | None no CRD number reported via UBS Financial Services Inc. (CRD 8174 ↗) | EDGAR ↗ |
| May 22, 2019 D Allovir, Inc. File 021-340180 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Oct 2, 2018 D Allovir, Inc. File 021-322562 | $0 | $0 | $6,837,146 Pursuant to Redeemable Preferred Stock Redemption Agreement | None listed on this filing | EDGAR ↗ |
| Feb 23, 2018 D MPM BIOVENTURES 2018 (B), L.P. File 021-306340 | $0 | $0 | $0 (est.) Certain persons named in Item 3 or affiliate(s) thereof may receive payments deemed to be made from the proceeds of the offering, including management fees. The amount of such payments cannot be estimated at this time. | None listed on this filing | EDGAR ↗ |
| Feb 22, 2018 D MPM BIOVENTURES 2018, L.P. File 021-306245 | $0 | $0 | $0 (est.) Certain persons named in Item 3 or affiliate(s) thereof may receive payments deemed to be made from the proceeds of the offering, including management fees. The amount of such payments cannot be estimated at this time. | None listed on this filing | EDGAR ↗ |
| Jul 9, 2015 D/A MPM BioVentures 2014, L.P. File 021-218237 | $140,000 | $0 | $0 An affiliate of the General Partner is entitled to a management fee payable by certain of the Issuers. | Dayna Gant BrokerCheck CRD 2126552 ↗ via Apple Lane Group LLC (CRD 129331 ↗) | EDGAR ↗ |
| Apr 7, 2015 D/A Clinical Ink, Inc. File 021-237218 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Mar 24, 2015 D/A MPM Bio 2014 NVS Strategic Fund, L.P. File 021-218238 | $0 | $0 | $0 An affiliate of the General Partner is entitled to a management fee payable by the Issuer. | None listed on this filing | EDGAR ↗ |
| Mar 5, 2015 D/A CHIASMA, INC File 021-230889 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Oct 24, 2013 D Sideris Pharmaceuticals, Inc. File 021-205211 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Oct 17, 2013 D Mitokyne, Inc. File 021-204791 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Sep 27, 2013 D Sideris Pharmaceuticals, Inc. File 021-203639 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Sep 5, 2013 D Oncology Investors of Texas CoStim, LLC File 021-202346 | $0 | $0 | $0 The Issuer's Manager (or its designee) is entitled to a management fee payable by the Issuer. | None listed on this filing | EDGAR ↗ |
| Jul 19, 2012 D Verastem, Inc. File 021-181480 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Nov 21, 2011 D/A Verastem, Inc. File 021-168567 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Jul 26, 2011 D Verastem, Inc. File 021-163437 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| May 31, 2011 D Radius Health, Inc. File 021-160578 | $434,868 | $0 | $0 | Leerink Swann LLC BrokerCheck CRD 39011 ↗ via Leerinks Swann LLC (CRD 39011 ↗) | EDGAR ↗ |
| May 31, 2011 D Radius Health, Inc. File 021-160580 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Nov 15, 2010 D/A Cerimon Pharmaceuticals, Inc. File 021-77816 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Feb 12, 2010 D MPM BIOVENTURES V, L.P. File 021-138701 | $0 | $0 | $0 A portion of the proceeds will be used to pay various fees and expenses to the General Partner over the life of the partnership, payable to MPM BioVentures V GP LLC, which serves as the sole General Partner of the Issuer. | None listed on this filing | EDGAR ↗ |
| May 28, 2009 D Elixir Pharmaceuticals, Inc. File 021-44911 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
Counts come from Form D Items 12–15 on the filings in our index (latest filing per offering; one offering = one SEC file number; an amendment updates its offering rather than adding one). "To insiders" = gross proceeds used for payments to executive officers, directors or promoters. "—" = not reported on that filing. Amounts marked (est.) were reported as estimates. "Paid to sell it" = sales compensation recipients named on that filing (Item 12), each linked to FINRA BrokerCheck when a CRD number is reported.
Counted across every filing this person is listed on (latest filing per offering, per issuer).
Every issuer that named Ansbert Gadicke on a Form D, newest first. A Form D is the notice a company files after it starts selling a private investment.
Raised $351M from 45 investors as of the latest filing. Ansbert is listed as executive officer on 2 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $80M from 15 investors (100% of the $80M target) as of the latest filing. Ansbert is listed as director.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $120.6M from 17 investors (40% of the $300M target) as of the latest filing. Ansbert is listed as director.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $326.8M from 31 investors as of the latest filing. Ansbert is listed as executive officer.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $125.4M from 36 investors (100% of the $125.4M target) as of the latest filing. Ansbert is listed as director.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Other Technology / 506(b) (17,390 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $98.9M from 36 investors (100% of the $98.9M target) as of the latest filing. Ansbert is listed as executive officer, promoter on 3 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $121.3M from 47 investors (100% of the $121.3M target) as of the latest filing. Ansbert is listed as director on 2 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
No sales reported yet as of the latest filing. Ansbert is listed as executive officer, promoter.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
No sales reported yet as of the latest filing. Ansbert is listed as executive officer, promoter.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $347.3M from 94 investors (100% of the $347.3M target) as of the latest filing. Ansbert is listed as director on 3 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $9.86M from 21 investors (100% of the $9.86M target) as of the latest filing. Ansbert is listed as director on 2 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Other / 506(b) (18,678 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $22.5M from 1 investor (100% of the $22.5M target) as of the latest filing. Ansbert is listed as director on 2 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $69.7M from 21 investors (80% of the $87.2M target) as of the latest filing. Ansbert is listed as director on 2 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $17M from 6 investors (53% of the $32M target) as of the latest filing. Ansbert is listed as director on 2 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pharmaceuticals / 506(b) (800 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $5.22M from 4 investors (12% of the $45M target) as of the latest filing. Ansbert is listed as director.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pharmaceuticals / 506(b) (800 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $1.73M from 7 investors (100% of the $1.73M target) as of the latest filing. Ansbert is listed as director.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.
Raised $100M from 36 investors (100% of the $2M target) as of the latest filing. Ansbert is listed as director on 4 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.
Raised $126.9M from 36 investors (100% of the $126.9M target) as of the latest filing. Ansbert is listed as director, promoter on 2 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.
Raised $1.5M from 10 investors (100% of the $250K target) as of the latest filing. Ansbert is listed as director on 5 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.
Raised $140M from 24 investors as of the latest filing. Ansbert is listed as promoter on 2 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.
Raised $12M from 36 investors (48% of the $25M target) as of the latest filing. Ansbert is listed as director.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.
Separate person records under the same name, not combined with this page. Each line says whether it shares an issuer with this record.
Officers, directors, promoters and management entities named on the same filings, as of Oct 23, 2026, 5:45 PM ET. Showing the 40 with the most shared filings.
Listed on the same filings as Ansbert Gadicke. Their page shows their other deals.
Listed on the same filings as Ansbert Gadicke. Their page shows their other deals.
Listed on the same filings as Ansbert Gadicke. Their page shows their other deals.
Listed on the same filings as Ansbert Gadicke. Their page shows their other deals.
Listed on the same filings as Ansbert Gadicke. Their page shows their other deals.
Listed on the same filings as Ansbert Gadicke. Their page shows their other deals.
Listed on the same filings as Ansbert Gadicke. Their page shows their other deals.
Listed on the same filings as Ansbert Gadicke. Their page shows their other deals.
Listed on the same filings as Ansbert Gadicke. Their page shows their other deals.
Listed on the same filings as Ansbert Gadicke. Their page shows their other deals.
Listed on the same filings as Ansbert Gadicke. Their page shows their other deals.
Listed on the same filings as Ansbert Gadicke. Their page shows their other deals.
Luke Evnin is on 21 issuers in total — a repeat sponsor. Their page lists every one.
Todd Foley is on 19 issuers in total — a repeat sponsor. Their page lists every one.
Vaughn Kailian is on 5 issuers in total — a repeat sponsor. Their page lists every one.
Listed on the same filings as Ansbert Gadicke. Their page shows their other deals.
Listed on the same filings as Ansbert Gadicke. Their page shows their other deals.
Listed on the same filings as Ansbert Gadicke. Their page shows their other deals.
Paul Hastings is on 5 issuers in total — a repeat sponsor. Their page lists every one.
Richard Aldrich is on 5 issuers in total — a repeat sponsor. Their page lists every one.
Christoph Westphal is on 15 issuers in total — a repeat sponsor. Their page lists every one.
Listed on the same filings as Ansbert Gadicke. Their page shows their other deals.
Stephen Kraus is on 7 issuers in total — a repeat sponsor. Their page lists every one.
Listed on the same filings as Ansbert Gadicke. Their page shows their other deals.
Listed on the same filings as Ansbert Gadicke. Their page shows their other deals.
Listed on the same filings as Ansbert Gadicke. Their page shows their other deals.
Henri Termeer is on 6 issuers in total — a repeat sponsor. Their page lists every one.
Listed on the same filings as Ansbert Gadicke. Their page shows their other deals.
Listed on the same filings as Ansbert Gadicke. Their page shows their other deals.
Listed on the same filings as Ansbert Gadicke. Their page shows their other deals.
Listed on the same filings as Ansbert Gadicke. Their page shows their other deals.
William Greene is on 11 issuers in total — a repeat sponsor. Their page lists every one.
Kurt Graves is on 7 issuers in total — a repeat sponsor. Their page lists every one.
Vincent Miles is on 5 issuers in total — a repeat sponsor. Their page lists every one.
Listed on the same filings as Ansbert Gadicke. Their page shows their other deals.
Listed on the same filings as Ansbert Gadicke. Their page shows their other deals.
One team, 2 deal companies. Ansbert Gadicke is listed on 2 of them.
Issuers are grouped when their Form D filings share related persons, a management entity or a business address (automatic match from the filings). "Listed" marks the issuers that name Ansbert Gadicke.
One team, 2 deal companies. Ansbert Gadicke is listed on 2 of them.
Issuers are grouped when their Form D filings share related persons, a management entity or a business address (automatic match from the filings). "Listed" marks the issuers that name Ansbert Gadicke.
One team, 3 deal companies. Ansbert Gadicke is listed on 1 of them.
Issuers are grouped when their Form D filings share related persons, a management entity or a business address (automatic match from the filings). "Listed" marks the issuers that name Ansbert Gadicke.
A shared address can mean the same team, a shared office building or a registered agent. It is a lead, not a conclusion.
A person is never an adviser firm. 3 of the 21 issuers this person is listed on match a Form ADV adviser (searched 24,962 advisers as of Oct 2, 2026): MPM BioVentures 2014, L.P., MPM Bio 2014 NVS Strategic Fund, L.P., Oncology Investors of Texas CoStim, LLC.
Searched SEC Regulation A Data Sets (Forms 1-A, 1-K, 1-Z; 2015 Q2 → 2026 Q3); SEC Crowdfunding Offerings Data Sets (Form C family; 2016 Q2 → 2026 Q3); EDGAR form index for 2026 Q3 → 2026 Q4 (51,358 records as of Oct 23, 2026, 8:41 PM ET) — nothing matched this name.
Property records are matched to companies only, never to individuals, so none are matched to Ansbert Gadicke by design. Searched property records in Hillsborough County FL (Clerk recorded-document index Oct 14, 2026 to Oct 15, 2026 + FL DOR 2026 ownership roll), Miami-Dade County FL (FL DOR 2026 ownership roll), Harris County TX (HCAD 2026 ownership roll), Dallas County TX (DCAD 2026 ownership roll), New York City ACRIS documents and PLUTO ownership rows already retrieved for other issuers, Cook County IL sale and ownership rows already retrieved for other issuers (814,874 records as of Oct 23, 2026, 8:59 PM ET) for the 21 issuers this person is listed on — nothing matched.
Websites and social links of the issuers Ansbert Gadicke is listed on: none on file. No website or social profile named in Oncology Impact Fund 2, L.P.'s SEC filings (Form C, Reg A, Form ADV; checked Oct 24, 2026). Web search for this name: #174,801 of 374,652 in line (452 issuers searched so far). One-tap searches: Look further ↓
One-tap searches on sites we do not index ourselves, with the name pre-filled (Cambridge, MA). Each opens in a new tab; what you find there is not verified by PartnerFacts.
No corrections have been requested for this page.
Free. Logged with status: received → under review → fixed / confirmed with source.
If this is you or your firm, add a sourced explanation next to any fact. Reviewed before publishing.
Members get an email when Ansbert Gadicke appears on a new Form D, or when a court case or SEC action is matched to them. See plans →